Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638058 | PMC |
| http://dx.doi.org/10.21037/jovs.2016.03.22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: The EXONERATE Study.
Clin Cancer Res
January 2025
City Of Hope National Medical Center, Monrovia, CA, United States.
PURPOSE EXONERATE (EXOsome and cell-free micro-RNAs of anti-EGFR ResistAnce) was an open-label, biomarker interventional study designed to develop, test, and validate a liquid biopsy predictive of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) for first-line EGFR inhibitors in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS Patients with newly diagnosed RAS-WT, chemotherapy-naïve mCRC, both right- and left-sided, were enrolled in 2-nationwide trials to receive cetuximab or panitumumab along with chemotherapy. The primary endpoint was 12-month PFS, which was hierarchically tested in left- and right-sided mCRC to predict PFS, OS, and ORR.
View Article and Find Full Text PDFRetraction Note: The role of nitric oxide during healing of trauma to the skeletal muscle.
Inflamm Res
December 2024
Serviço de Reumatologia, Laboratory of Molecular Biology ofAutoimmune and Infectious Disease, Hospital de Clínicas dePorto Alegre (HCPA), Universidade Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos 2350, 6° andar/sala645, Porto Alegre, RS, 90035-003, Brazil.
SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023).
Clin Transl Oncol
November 2024
Medical Oncology Department, Hospital Clínico Universitario de Valencia, INCLIVA, Valencia, Spain.
Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, the incidence is lower and GC represents the tenth most frequent tumor and the seventh cause of cancer mortality. Molecular biology knowledge allowed to better profile patients for a personalized therapeutic approach.
View Article and Find Full Text PDFHypertension as predictive factor for bevacizumab-containing first-line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011-04) study.
Clin Transl Oncol
August 2024
GEICAM Spanish Breast Cancer Group, Madrid, Spain.
Background: Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.
Methods: This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment.
Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial.
World J Gastrointest Oncol
February 2024
Department of Medical Oncology, Hospital Universitario de Torrejon, Madrid 28850, Spain.
Background: The prognostic value of the Systemic Inflammation Response Index (SIRI) in advanced pancreatic cancer is recognized, but its correlation with patients´ nutritional status and outcomes remains unexplored.
Aim: To study the prognostic significance of SIRI and weight loss in metastatic pancreatic cancer.
Methods: The PANTHEIA-Spanish Society of Medical Oncology (SEOM) study is a multicentric (16 Spanish hospitals), observational, longitudinal, non-interventional initiative, promoted by the SEOM Real World-Evidence work group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!